Bright Green Corp banner

Bright Green Corp
NASDAQ:BGXX

Watchlist Manager
Bright Green Corp Logo
Bright Green Corp
NASDAQ:BGXX
Watchlist
Price: 0.038 USD -2.56% Market Closed
Market Cap: $130k

EV/EBIT

-0.1
Current
No historical data
Comparison unavailable

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
-0.1
=
Enterprise Value
$894.9k
/
EBIT
$-6m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
-0.1
=
Enterprise Value
$894.9k
/
EBIT
$-6m

Valuation Scenarios

Bright Green Corp is trading above its industry average

If EV/EBIT returns to its Industry Average (12.1), the stock would be worth $-3.08 (8 201% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-13 243%
Maximum Upside
No Upside Scenarios
Average Downside
10 722%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple -0.1 $0.04
0%
Industry Average 12.1 $-3.08
-8 201%
Country Average 19.6 $-4.99
-13 243%

Forward EV/EBIT
Today’s price vs future ebit

Not enough data available to calculate forward EV/EBIT

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
US
Bright Green Corp
NASDAQ:BGXX
130k USD -0.1 -0
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 29.2 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 21.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.4 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 21.9 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.6 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 11.5 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 970 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 9.8 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 10.1 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 8.9 16.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Bright Green Corp
NASDAQ:BGXX
Average EV/EBIT: 111.2
Negative Multiple: -0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.2
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.4
13%
1.6
CH
Roche Holding AG
SIX:ROG
13.4
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
21.9
21%
1
CH
Novartis AG
SIX:NOVN
15.6
9%
1.7
US
Merck & Co Inc
NYSE:MRK
11.5
6%
1.9
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
2%
4.9
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.9
-6%
N/A
P/E Multiple
Earnings Growth PEG
US
Bright Green Corp
NASDAQ:BGXX
Average P/E: 21.9
Negative Multiple: -0
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 8 638 companies
0th percentile
-0.1
Low
0 — 13.6
Typical Range
13.6 — 27.8
High
27.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.6
Median 19.6
70th Percentile 27.8
Max 1 826 183.2

Bright Green Corp
Glance View

Market Cap
130k USD
Industry
Pharmaceuticals

Bright Green Corp is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Grants, Florida. The company went IPO on 2022-05-17. Bright Green Corporation is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured in exact formulations for research and pharmaceutical applications, as well as ingredient to consumer-based solutions. The firm is engaged in cannabis propagation, cultivation, and manufacturing of cannabis products including cannabis flower, pre-rolls, concentrates, vape pens, capsules, tinctures, edibles, topicals and any other cannabis-related products requested for authorized sales. The firm plans to sell extracted oils from medicinal plants grown in these high-tech facilities and processed onsite through a proprietary system that vertically integrates the genetically altered growth of the plants to conform to automated growing systems. The company also plans to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).

BGXX Intrinsic Value
Not Available
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett